Schizophrenia is a serious mental illness that affects approximately 1% of the world’s adult population. The disease often begins in early adulthood and frequently results in a lifetime struggle with episodes of positive symptoms such as delusions and hallucinations.
In many people with schizophrenia, when positive symptoms are reduced or in remission due to antipsychotics or the cyclical nature of the disease, negative symptoms such as social withdrawal and cognitive impairment remain and cause high levels of disability. A number of the most widely used antipsychotics have pharmacologic properties that may contribute to these problems by causing drowsiness or blocking other receptors in the brain involved in cognition. Other common side effects of the most effective antipsychotics include significant weight gain, diabetes, high cholesterol or triglycerides, and movement disorders that mimic Parkinson’s Disease. It is not unusual for patients with schizophrenia to stop taking their medications due to these side effects which frequently leads to the re-emergence of positive symptoms. LB-102 is an antipsychotic from a class of drugs called benzamides.
There are several benzamide antipsychotics in use throughout the word including amisulpride, sulpiride, sultopride, tiapride, and levosulpiride. LB-102 is designed to potentially retain the effectiveness of the most effective antipsychotics with less of the troublesome side effects that decrease a patients overall well-being. In order to understand how, visit our knowledge base.